Venture Partner
Richard A. Heyman, Ph.D., is a scientist with 25 years of experience in the biotech and life science field. Recently, Rich co-founded and serves as Chairman of Architect Therapeutics, a small molecule drug discovery company applying novel chemical editing technologies to expand the druggable space. Previously, he served as Chairman of Vividion Therapeutics, purchased by Bayer Pharma, Amunix Pharma, purchased by Sanofi and Rayze Bio purchased by BMS. He is the co-founder and Chairman of ORIC Pharmaceuticals and serves as Chairman of Enliven Therapeutics and PMV Pharma. Earlier in his career, Rich was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, which focused on therapies for hormone dependent cancers. He has been involved in the discovery and development of multiple FDA approved therapies, including the prostate cancer drug, Erleada. Rich is a Venture/Science Partner for Arch Ventures and Nextech Invest. Outside his corporate experience, Rich is on the Board at the Salk Institute and the UCSD Moores Cancer Center and a founding member of both Life Science Cares, San Diego and Curebound. He has won numerous awards including E&Y San Diego Regional Entrepreneur of the Year and is the author or inventor on more than 125 publications and patents.